Wide medicine group hand in hand "the Nobel Prize winner jose vladimir innovation research and development of traditional Chinese medicine (TCM)

Source: China stock certificate report

        On September 21, afternoon, the broad medicine group invited guangzhou medicine research institute President, Nobel Prize winner of caphtor reed · jose vladimir radmanovic in dr sun yat-sen university held a "the Nobel masters talk about health" medical lectures, this is the broad medicine group and guangzhou university of Chinese medicine after signed strategic cooperation agreement effective communication and promotion of scientific and technological achievements and a move.

        The Nobel Prize winner leading the "big NaYao" strategy for propulsion

        Fritz DE jose vladimir doctor is the winner of the 1998 Nobel Prize in physiology medicine, is well-known drug "viagra" theory inventor, has "the father of viagra" reputation. In January 2012, wide medicine group officially employ fritz DE jose vladimir doctor as wide medicine institute first dean. jose

        Radmanovic bo as wide medicine group guangzhou medicine research institute President later, has already begun to use the Nobel Prize nitric oxide technology, the broad medicine group compound salvia miltiorrhiza tablet, hua tuo restorative pill and a number of disease of heart head blood-vessel well-known drug effect mechanism of the depth of research, the results of this study would promote wide medicine group disease of heart head blood-vessel drug secondary development. In the future, nitric oxide technology is more likely to use to the broad medicine group of other areas of product development.

        Jose rudd said: "for the broad medicine institute, the technical team hopes to use the Nobel Prize nitric oxide technology improve the broad medicine group many famous product technology content, speeds up the broad medicine group development speed, help them become world famous pharmaceutical enterprise group."

        Wide medicine group in scientific research innovation consistent in the domestic leading position, in the "traditional Chinese medicine extraction and separation process modern national engineering research center", "modern Chinese medicine extraction and separation and purification high-tech industrialization demonstration base construction", "national guangzhou new drug preclinical safety evaluation of key laboratory" and so on national larger project construction and cephalosporin sulfur amidine, treatment type double plasmid HBV DNA vaccine, lyophilization people with rabies vaccine and a large number of major innovation drugs and Chinese traditional Chinese medicine academy of sciences and the Chinese academy of medical sciences, Beijing university, tsinghua university and other domestic first-class colleges and universities to establish a broad strategic cooperation and project cooperation, and achieved significant results. In this year at the fifth china-us pharmacopoeia international BBS, the broad medicine group implement standardization strategy for Chinese and foreign expert's consistent high praise. At the same time, such as diabetes drug research advances with steady steps, the distribution of global GAP medicinal materials base expanded to more than 30 place.

        It is reported, current jose radmanovic led dr research team is working with wide medicine group research team use the Nobel Prize technology to develop treatment disease of heart head blood-vessel drug research and secondary development, wide drug groups on the strong joint are full of confidence.

        The first domestic innovation fund boosting innovation achievements of traditional Chinese medicine (TCM) is beginning

        In the latest ministry of health issued by the health China 2020 strategy research report puts forward "innovation of traditional Chinese medicine" specific goals. Wide medicine group takes the lead in putting forward "revitalization of the big NaYao", get the ministry of health, the ministry of science and technology, the state food and drug administration and national administration of traditional Chinese medicine and other relevant state departments of the highly recognized. On January 9, 2012, wide medicine group with international standards for the construction of the development platform, initial investment of 100 million yuan, in the domestic first established the "big NaYao" innovation fund, to promote extensive drug group big projects and large varieties of research and development.

        "Big NaYao" innovation fund to boost the broad medicine of traditional Chinese medicine research and development group of innovation, the new drug research progress is remarkable, and the new drug of TCM in the treatment of diabetes "rhizoma anemarrhenae polyphenol capsule" project has been completed Ⅱ a period clinical research, new drug of TCM treatment of RA "glabrous greenbrier rhizome total glycosides tablet" project has been completed Ⅱ a period clinical trials, major innovation drug "complex plug pass tablet" project has completed related pharmacology, toxicology and quality control technology research, tumor auxiliary medicine Chinese traditional medicine 5 kinds of new drug "ganoderma lucidum spore oil injection" has completed the ganoderma lucidum spore oil extraction technology research, the main chemical composition analysis and appraisal, quality control method and HPLC fingerprint and so on many research, gynecology of traditional Chinese medicine for external use six kind of new drug "woman green snow lotus bolt" already completed five center Ⅱ phase of clinical test.

        It is reported, jose radmanovic led research team is wide medicine group's hua tuo restorative pill, complex these raw piece, bezoar chest functioning pill, quench pill and so on several famous traditional Chinese medicine in mechanism research, jose vladimir doctor is expected to end in research in the research results, and help our country quality Chinese medicine products to the European and American market.         

        Wide medicine group general manager LiChuYuan think, "1025" period, the broad medicine group through the "136" development strategy and 11 x development model, the economic scale unceasingly expands, the creative ability of science and technology continuously strengthen. At present, the broad medicine group is to explore and establish talent attraction and incentive mechanism, talent cultivation measures to promote and enhance the major scientific research project development and management, and to fine a batch of famous traditional Chinese patent medicine participate in market competition, and formed the highlight of our country traditional Chinese medicine industry and characteristic.

        Sales next year to break 50 billion yuan

        According to understand, just on the Chinese pharmaceutical industry top the top of the broad medicine group, in the macroeconomic continue downward, medicine industry growth is slowing of the environment, in the first half of the sales revenue and profits remain above 20% of growth, the growth are super provinces industrial enterprises above designated size and medical industry average.

        Wide medicine group general manager LiChuYuan said, the first half of the overall performance steady growth thanks mainly to a "136 development strategy" and "11 x development model" implementation, the broad medicine group whole appears on the market is steadily as planned, the second half of wide medicine group will be "baiyun mountain" brand as the core, give full play to "baiyun mountain" marketization and national brand advantage, stimulate guangzhou pharmaceutical resources superiority and the historical precipitation potential, implement large NaYao strategy. Meanwhile, red tank and red bottle WangLaoJi regression wide medicine, will reshape the broad medicine value, wide medicine group will use a value 108 billion yuan "WangLaoJi" brand, the integration of the subordinate enterprise resources, to the big health industry hair force.

        It is reported, wide medicine group next year is expected to more than 50 billion sales, it is estimated that by 2020, the sales revenue will achieve 150 billion, into the world 500 strong, become the largest Chinese medicine, the most complete industry chain, the most perfect marketing network, development of the strongest comprehensive strategic emerging industry leading enterprises.